BC Pharmacare to cover SGLT-2 inhibitors and to delist the Lantus brand of insulin glargine U100
Announcements, Living With Diabetes
Yesterday BC Minister of Health Adrian Dix announced Pharmacare coverage of the SGLT-2 inhibitor class represented by empagliflozin (Jardiance). Although BCDiabetes would have preferred that all three SGLT2 inhibitors on the Canadian market be covered, the long overdue announcement was most welcome news. Our readers will be aware of the long-running BCDiabetes advocacy campaign for […]